Company intelligence / Profile preview
Ono Pharmaceutical
Osaka City / Chuo-ku district, Osaka Prefecture, Japanono-pharma.com ↗
- Ownership
- Public · 4528
- Employees
- ~3687
- Development stage
- Commercial
01
Overview
ONO’s most notable product is Opdivo® (nivolumab), a pioneering PD‑1 immune checkpoint inhibitor for cancer treatment developed in collaboration with Bristol Myers Squibb. The company has a robust pipeline in oncology, immunology, neurology, and specialty areas with several late-stage clinical programs and ongoing global expansion efforts[4][5][7]. In FY2023 revenue was approximately USD $2.4–$6.3 billion depending on exchange rates reported; Opdivo remains the primary growth driver[4][5].
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Small moleculesmonoclonal antibodies (notably immune checkpoint inhibitors)other biologics
- Industry
- Pharma
02
Drug pipeline
66 assets65 more assets in the full pipeline.
Request access →03
Partnerships
Bristol Myers Squibb (co-development/commercialization of Opdivo/nivolumab)Harvard University Office of Technology Development for joint research/drug development agreement signed in early 2024
Beyond the preview
Go deeper on Ono Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ono Pharmaceutical.